Clinical Trial Update: A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma [Phase 1]

View source ↗

Summary

A Phase I study evaluating vorinostat in combination with bevacizumab and irinotecan for recurrent glioblastoma. The trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Irinotecan (Irinotecan)
• Vorinostat (vorinostat)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Glioblastoma | Phase 1 | Status: COMPLETED